Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 32

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 32
---
    Penalty for late S-1 filing and effectiveness 
     55,000  
     55,000 
  
    Accrued clinical expenses 
     87,099  
     - 
  
    Accrued consulting, professional services and other 
     75,729  
     941,600 

    $340,691  
    $1,913,175 

NOTE 7 – LEASES

As of September 30, 2025
and December 31, 2024, the Company holds a five-year lease for laboratory and office space. The lease has escalating contractual rent
and variable rent components and the Company elected to separate the contractual and variable elements for valuing the operating lease
liability and right-to-use asset. The lease does not have any options for extension or expansion. The Company recorded the following lease
costs:

    For the three months ended 
September 30,  
    For the nine months ended September 30,  
    For the period from February 14, 2024
    through September 30,  
    For the period from January 1, 2024
    through February 13, 

    2025  
    2024  
    2025  
    2024  
    2024 

    (Successor)  
    (Successor)  
    (Successor)  
    (Successor)  
    (Predecessor) 
  
    Operating leases: 

    Operating lease cost 
    $226,880  
    $229,331  
    $685,542  
    $585,702  
    $110,885 
  
    Variable operating lease cost 
     187,730  
     177,056  
     600,334  
     441,560  
     84,401 
  
    Total lease cost 
    $414,610  
    $406,387  
    $1,285,876  
    $1,027,262  
    $195,286 

The right-of-use asset, net for the operating lease was recorded in
the condensed consolidated balance sheets as follows:

    September 30,  
    December 31, 

    2025  
    2024 

    (Successor)  
    (Successor)